MGAT3 mRNA: A biomarker for prognosis and therapy of Alzheimer's disease by vitamin D and curcuminoids

Journal of Alzheimer's Disease

Volumn 25, Issue 1, 2011, Pages 135-144

  Fiala, Milan ^a,d   Mahanian, Michelle ^a   Rosenthal, Mark ^a   Mizwicki, Matthew T ^b   Tse, Eric ^a   Cho, Tiffany ^a   Sayre, James ^c   Weitzman, Rachel ^a   Porter, Verna ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; amyloid ; MGAT3; surgical anesthesia; vitamin D3

Indexed keywords

AMYLOID BETA PROTEIN; BETA 1,4 MANNOSYLGLYCOPROTEIN 4 BETA N ACETYLGLUCOSAMINYLTRANSFERASE; BIOLOGICAL MARKER; CALCITRIOL; CELL NUCLEUS RECEPTOR; CHOLINESTERASE INHIBITOR; COLECALCIFEROL; DIDEMETHOXYCURCUMIN; MESSENGER RNA; N ACETYLGLUCOSAMINYLTRANSFERASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

AGED; ALZHEIMER DISEASE; ANESTHESIA; ARTICLE; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; CONVALESCENCE; DISEASE COURSE; DOWN REGULATION; DRUG MEGADOSE; ESSENTIAL GENE; FEMALE; HUMAN; HUMAN CELL; MACROPHAGE; MINI MENTAL STATE EXAMINATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PHAGOCYTOSIS; PRIORITY JOURNAL; PROGNOSIS; RNA TRANSCRIPTION; UPREGULATION;

EID: 79959652671     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-101950     Document Type: Article

References (31)

1. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, Rabinovici GD, Robinson WH, Sabbagh MN, So YT, Sparks DL, Tabaton M, Tinklenberg J, Yesavage JA, Tibshirani R, Wyss-Coray T (2007) Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 13, 1359-1362. (Pubitemid 350073592)
2. Marksteiner J, Kemmler G, Weiss EM, Knaus G, Ullrich C, Mechtcheriakov S, Oberbauer H, Auffinger S, Hinterholzl J, Hinterhuber H, Humpel C (2009) Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease. Neurobiol Aging, Doi:10.1016/j.neurobiolaging.2009.03.011
3. Nordberg A, Rinne JO, Kadir A, Langstrom B (2010) The use of PET in Alzheimer disease. Nat Rev Neurol 6, 78-87.
4. Hertze J, Minthon L, Zetterberg H, Vanmechelen E, Blennow K, Hansson O (2010) Evaluation of CSF biomarkers as predictors of Alzheimer's disease: A clinical follow-up study of 4.7 years. J Alzheimers Dis 21, 1119-1128.
5. Fiala M, Liu PT, Espinosa-Jeffrey A, Rosenthal MJ, Bernard G, Ringman JM, Sayre J, Zhang L, Zaghi J, Dejbakhsh S, Chiang B, Hui J, Mahanian M, Baghaee A, Hong P, Cashman J (2007) Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimer's disease patients are improved by bisdemethoxycurcumin. Proc Natl Acad Sci U S A 104, 12849-12854. (Pubitemid 47255243)
6. Cataldo AM, Mathews PM, Boiteau AB, Hassinger LC, Peterhoff CM, Jiang Y, Mullaney K, Neve RL, Gruenberg J, Nixon RA (2008) Down syndrome fibroblast model of Alzheimer-related endosome pathology: Accelerated endocytosis promotes late endocytic defects. Am J Pathol 173, 370-384.
7. Cataldo A, Rebeck GW, Ghetri B, Hulette C, Lippa C, Van Broeckhoven C, van Duijn C, Cras P, Bogdanovic N, Bird T, Peterhoff C, Nixon R (2001) Endocytic disturbances distinguish among subtypes of Alzheimer's disease and related disorders. Ann Neurol 50, 661-665. (Pubitemid 33021925)
8. Avagyan H, Goldenson B, Tse E, Masoumi A, Porter V, Wiedau-Pazos M, Sayre J, Ong R, Mahanian M, Koo P, Bae S, Micic M, Liu PT, Rosenthal MJ, Fiala M (2009) Immune blood biomarkers of Alzheimer disease patients. J Neuroimmunol 210, 67-72.
9. Piccini C, Bracco L, Falcini M, Pracucci G, Amaducci L (1995) Natural history of Alzheimer's disease: Prognostic value of plateaux. J Neurol Sci 131, 177-182.
10. Cortes F, Nourhashemi F, Guerin O, Cantet C, Gillette- Guyonnet S, Andrieu S, Ousset PJ, Vellas B (2008) Prognosis of Alzheimer's disease today: A two-year prospective study in 686 patients from the REAL-FR Study. Alzheimers Dement 4, 22-29.
11. Welsh KA, Butters N, Hughes JP, Mohs RC,HeymanA(1992) Detection and staging of dementia in Alzheimer's disease. Use of the neuropsychological measures developed for the Consortium to Establish a Registry for Alzheimer's Disease. Arch Neurol 49, 448-452.
12. Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, Smith GE, Younkin LH, Petersen RC, Younkin SG (2007) Association of lowplasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 64, 354-362. (Pubitemid 46425689)
13. Lambert JC, Schraen-Maschke S, Richard F, FievetN, Rouaud O, Berr C, Dartigues JF, Tzourio C, Alperovitch A, Buee L, Amouyel P (2009) Association of plasma amyloid beta with risk of dementia: The prospective Three-City Study. Neurology 73, 847-853.
14. Lewczuk P, Kornhuber J, Vanmechelen E, Peters O, Heuser I, Maier W, Jessen F, Burger K, Hampel H, Frolich L, Henn F, Falkai P, Ruther E, Jahn H, Luckhaus C, Perneczky R, Schmidtke K, Schroder J, Kessler H, Pantel J, Gertz HJ, Vanderstichele H, de Meyer G, Shapiro F, Wolf S, Bibl M, Wiltfang J (2010) Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing. Exp Neurol 223, 366-370.
15. Laske C, Sopova K, Gkotsis C, Eschweiler GW, Straten G, Gawaz M, Leyhe T, Stellos K (2010) Amyloid-beta peptides in plasma and cognitive decline after 1 year follow-up in Alzheimer's disease patients. J Alzheimers Dis 21, 1263-1269.
16. Zaghi J, Goldenson B, Inayathullah M, Lossinsky AS, Masoumi A, Avagyan H, Mahanian M, Bernas M, Weinand M, Rosenthal MJ, Espinosa-Jeffrey A, de Vellis J, Teplow DB, Fiala M (2009) Alzheimer disease macrophages shuttle amyloid-beta from neurons to vessels, contributing to amyloid angiopathy. Acta Neuropathol 117, 111-124.
17. Akasaka-Manya K, Manya H, Sakurai Y, Wojczyk BS, Kozutsumi Y, Saito Y, Taniguchi N, Murayama S, Spitalnik SL, Endo T (2010) Protective effect of N-glycan bisecting GlcNAc residues on beta-amyloid production in Alzheimer's disease. Glycobiology 20, 99-106.
18. Bhattacharyya R, Bhaumik M, Raju TS, Stanley P (2002) Truncated, inactive N-acetylglucosaminyltransferase III (GlcNAc-TIII) induces neurological and other traits absent in mice that lack GlcNAc-TIII. J Biol Chem 277, 26300-26309. (Pubitemid 34967121)
19. Mandrekar S, Jiang Q, Lee CY, Koenigsknecht-Talboo J, Holtzman DM, Landreth GE (2009) Microglia mediate the clearance of soluble Abeta through fluid phase macropinocytosis. J Neurosci 29, 4252-4262.
20. Paresce DM, Chung H, Maxfield FR (1997) Slowdegradation of aggregates of the Alzheimer's disease amyloid beta-protein by microglial cells. J Biol Chem 272, 29390-29397. (Pubitemid 27498234)
21. HolickMF(2008)Vitamin D: A D-Lightful health perspective. Nutr Rev 66, S182-S194.
22. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, Ochoa MT, Schauber J,Wu K, Meinken C, Kamen DL,Wagner M, Bals R, Steinmeyer A, Zugel U, Gallo RL, Eisenberg D, Hewison M, HollisBW, Adams JS, Bloom BR, Modlin RL (2006) Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311, 1770-1773.
23. Mizwicki MT, Norman AW (2009) The vitamin D sterolvitamin D receptor ensemble model offers unique insights into both genomic and rapid-response signaling. Sci Signal 2, re4.
24. Llewellyn DJ, Lang IA, Langa KM, Muniz-Terrera G, Phillips CL, Cherubini A, Ferrucci L, Melzer D (2010) Vitamin D and risk of cognitive decline in elderly persons. Arch Intern Med 170, 1135-1141.
25. Masoumi A, Goldenson B, Ghirmai S, Avagyan H, Zaghi J, Abel K, Zheng X, Espinosa-Jeffrey A, Mahanian M, Liu PT, Hewison M, Mizwicki M, Cashman J, Fiala M (2009) 1alpha,25-dihydroxyvitamin D3 interacts with curcuminoids to stimulate amyloid-beta clearance by macrophages of Alzheimer's disease patients. J Alzheimers Dis 17, 703-717.
26. Dursun E, Gezen-Ak D, Yilmazer S (2011) A novel perspective for Alzheimer's disease: Vitamin D receptor suppression by amyloid-beta and preventing the amyloid-beta induced alterations by vitamin D in cortical neurons. J Alzheimers Dis 23, 207-219.
27. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
28. Mizwicki MT, Bula CM, Mahinthichaichan P, Henry HL, Ishizuka S, Norman AW (2009) On the mechanism underlying (23S)-25-dehydro-1alpha(OH)-vitamin D3-26,23- lactone antagonism of hVDRwt gene activation and its switch to a superagonist. J Biol Chem 284, 36292-36301.
29. Monney L, Sabatos CA, Gaglia JL, Ryu A,Waldner H, Chernova T, Manning S, Greenfield EA, Coyle AJ, Sobel RA, Freeman GJ, Kuchroo VK (2002) Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 415, 536-541. (Pubitemid 34130609)
30. Gouin JP, Hantsoo L, Kiecolt-Glaser JK (2008) Immune dysregulation and chronic stress among older adults: A review. Neuroimmunomodulation 15, 251-259.
31. Moller JT, Cluitmans P, Rasmussen LS, Houx P, Rasmussen H, Canet J, Rabbitt P, Jolles J, Larsen K, Hanning CD, Langeron O, Johnson T, Lauven PM, Kristensen PA, Biedler A, van Beem H, Fraidakis O, Silverstein JH, Beneken JE, Gravenstein JS (1998) Long-term postoperative cognitive dysfunction in the elderly ISPOCD1 study. ISPOCD investigators. International Study of Post-Operative Cognitive Dysfunction. Lancet 351, 857-861. (Pubitemid 28121173)